Anti-biofilm Wound Dressing Market

Anti-biofilm Wound Dressing Market Outlook (2023 to 2033)

The net worth of the market share of the anti-biofilm wound dressing is predicted to reach from US$ 782.60 million in 2023 to over US$ 1939.45 million by 2033, recording a CAGR of 9.5% between 2023 and 2033. Incidence rates for chronic and acute wounds are expected to increase, driving demand for anti-biofilm wound dressings.

As chronic diseases such as diabetes, cancer, and other autoimmune diseases become prevalent. Antimicrobial resistance and unhealthy sedentary lifestyles, tobacco, and alcohol consumption are also contributing to the rising non-communicable disease prevalence.

A study published by the Centres for Disease Control and Prevention in 2020. The report estimates that there are 34.2 million diabetics in the United States which is 10.5% of the population. An estimated 26.8 million people in the United States have been diagnosed with diabetes. However, 7.3 million people have not yet been diagnosed with diabetes, according to a similar report.

Anti-biofilm Wound Dressing Market Dynamics

• Telehealth has played a key role in the strong recovery of the wound care market. Various healthcare providers have developed telehealth platforms to effectively manage patients with chronic and acute wounds.
• A growing number of chronic and acute wounds caused by chronic diseases (such as diabetes, venous, or arterial disorders) show bacterial contamination films on their surface. This is expected to drive market growth over the forecast period. Hospital-Acquired Pressure Injury (HAPI) accounts for 8.4% of patients with pressure ulcers, according to research published by the National Centre for Biotechnology Information in June 2022.
• Several other factors contributing to the market's growth include the development of healthcare infrastructure across developing countries, technological advancements in wound management, and the efforts taken by healthcare providers and key players to increase awareness of wound care.

For instance, according to ASEP Medical Holdings Inc., the Antibiofilm/Anti-inflammatory Peptide Technology that was developed with help from the United States Army Medical Research and Materiel Command was successful in February 2022.

• Market growth is expected to be hampered by high costs associated with wound care treatment and a shortage of skilled professionals.

Global Anti-biofilm Wound Dressing Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)

According to the World Health Organization, cancer is the leading cause of death worldwide, killing one in six people every year. More than 70 percent of cancer-related deaths occur in countries with low or middle-income groups. Increased incidences of chronic diseases result in prolonged hospitalizations and surgeries, which would increase the demand for anti-biofilm wound dressings.

Due to the increasing participation in sports, injuries are becoming more common. For example, Stanford Children's Health estimates that about 3.5 million injuries occur among children in the United States every year and 21 percent of these injuries are traumatic in nature.

The Canadian Institute for Health Information (CIHI) reports that more than 17,655 individuals have been hospitalized for sports-related injuries in 2017. Therefore, more injuries are occurring to fuel the demand for the global market.

• Short Term (2022 to 2025): There is an increase in the number of patients suffering from various disorders due to pandemics, such as eating habits, sedentary lifestyles, and changes in regimes. These factors are negatively impacting human health, leading to chronic diseases such as cancer and diabetes, which are driving the global market.
• Medium Term (2025 to 2028): A rising number of people are seeking wound care products, such as anti-biofilm wound dressings, at home. The elderly population is at a significantly higher risk of infection, and the demand for home healthcare products is growing. A growing number of people are turning to online therapies for assistance with their health problems. This is likely to propel the market for anti-biofilm wound dressings into the future.
• Long Term (2028 to 2033): The market is predicted to expand during the forecast period due to well-developed healthcare infrastructure and favorable reimbursement policies.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Major Factors Driving the Anti-biofilm Wound Dressing Market

• Diabetes Prevalence to Drive Growth of the Market in the Future

The incidence of diabetic foot ulcers in diabetics ranges from 2% to 10%, according to studies conducted by B Braun Melsungen AG in 2018. The American College of Physicians reports that the number of newly diagnosed cases of diabetic foot ulcers was about 6.3% in 2017. The incidence of diabetic foot ulcers in a lifetime varies from 19% to 34%. Since anti-biofilm dressings are highly recommended for treating chronic wounds, market growth is expected to grow at a high rate.

Most surgical wounds following cancer surgery are deep and large, resulting in exudates that need to be managed daily. As a result, the growing prevalence of chronic illnesses is expected to boost product demand, thus pushing the global anti-biofilm wound dressing market upward. Anti-biofilm wound dressings, such as iodine and silver-based wound dressings, help manage wounds and prevent infection.

according to the World Health Organization (WHO)., about 1,000,000 Indians are affected by serious or moderate burns in India each year, The market may grow due to the rise in injuries caused by road accidents, trauma events, and burns around the globe.

• Increasing Prevalence of Chronic Wounds

With the rise of chronic diseases like cancer, diabetes, and Deep Vein Thrombosis (DVT), the likelihood of acquiring chronic wounds rises, which is expected to drive market growth. Diabetic foot ulcers are wounds that typically occur in 15% of diabetic patients.

About 6% of these people are hospitalized due to infection, thus wound treatment is necessary. According to the National Cancer Institute, in 2018, there were 1,735,350 diagnosed cancer cases in the United States. Due to the rise in cancer cases, the demand for anti-biofilm wound dressings may increase.

In the United States, approximately 900,000 people are affected by DVT each year. With the rising prevalence of DVT, patients are more likely to develop venous ulcers. Approximately 20 to 50 percent of them may experience Post-thrombotic Syndrome (PTS), and 5% to 10% may suffer from venous ulcers.

The market is expected to expand further due to the increasing prevalence of pressure ulcers, commonly referred to as bed sores or pressure sores. According to the European Pressure Ulcer Advisory Panel, 5% of community nursing patients and 10% of hospital patients may develop pressure ulcers at some point in their lives. Therefore, the growing prevalence of chronic ulcers is expected to propel the demand for the anti-biofilm wound dressing market.

• Ambulatory Surgery Centers are Becoming More Popular

Through the provision of low-risk procedures in a convenient setting, Ambulatory Surgical Centers (ASCs) are revolutionizing healthcare delivery. Thus offering lower costs than other medical settings, such as hospitals, ASCs are anticipated to grow in popularity as Medicare spends more on improving ASCs.

Over 3.4 million Medicare Fee-For-Service (FFS) beneficiaries were treated in 5,603 hospitals certified by Medicare in 2017. Medicare beneficiaries spent US$ 4.6 billion on ASC services in 2017. A growing number of ASCs is expected to drive the overall market. Previously, ASCs offered a single specialty.

There has been an increase in multispecialty ASCs in the United States from 1,802 in 2015 to 1,878 in 2017, as these settings are increasingly used for different applications. Market growth is expected to be driven by the fact that they can perform special treatments, including pain management, orthopedics, and ophthalmology.

Major Restrain Faced by Anti-biofilm Wound Dressing Market: The Rise in Treatment Cost

The number of wound patients occupying hospital beds is approximately 25% to 40%. A wound takes a long time to heal and requires many resources. The human cost associated with wounds is prolonged hospital stays, chronic pain, and distress.

For example, a stage IV pressure ulcer causes considerable pain, adding around three months or longer to hospital stays, thereby increasing the patient burden. Similarly, wound infections can lead to inflammation and pain, which will require surgical intervention or anti-biofilm dressings to prevent wound infections from developing.

The cost of wound care in acute settings can reach 15% to 20% of materials, 30% to 35% of nurse time, and more than 50% of hospitalization. The wound dressings must be changed frequently, which adds to the cost of treatment.

It is estimated that chronic wounds cost between US$ 3.48 million and US$ 4.32 million per year, accounting for about 2% to 3% of the healthcare budget. As a result, high treatment costs may result in a decrease in the adoption of anti-biofilm wound dressings, which, in turn, may hinder the market growth during the forecast period.

Major Opportunities for Anti-biofilm Wound Dressing Market: Rise in Accident Cases

Approximately 50 million people are affected annually by vehicle accidents, including slips, trips, burns, and road accidents. Wound dressings that promote wound healing and are anti-biofilm, the market is driven by the increase in accidents, slips, trips, burns, and other ailments.

Health and Safety Middle East (HSME) indicates that hundreds of workers suffer injuries in the workplace each year as a result of trips, slips, and falls. An increase in burn injuries is also expected to drive the market's growth. It is estimated that 1.1 million burn injuries occur in the United States every year. Approximately 50,000 of these patients require hospitalization, which increases the need for wound dressings with anti-biofilms.

Anti-biofilm Wound Dressing Market Category-Wise Insights

The global anti-biofilm wound dressing devices market is segmented by mode of mechanism, wound type, end-user, and region.

Expanding the Penetration of Chemical Segment:

Based on the Mode of Mechanism: The global anti-biofilm wound dressing devices market has been segmented into physical, chemical, and biological. The chemical segment is expected to dominate the overall market and record a significant CAGR of 9.9% during the forecast period.

The chemical mode of mechanism is expected to expand substantially over the forecast period. There is a growing prevalence of chronic wounds and a growing number of surgeries worldwide, so this is inevitable.

A chemical-based anti-biofilm wound dressing improves wound healing efficiency and recovery efficiency by targeting biofilms on multiple levels. They can reduce the accumulation of biofilm on wounds and reduce the risk of recontamination with microorganisms.

A significant increase in Research and Development activities and innovation is taking place in the anti-biofilm wound dressing industry, which is fuelled by the physical mode of mechanism. It was announced in June 2020 that the United Kingdom National Biofilms Innovation Centre would be providing a grant of US$ 28,949.03 million for research and the introduction of enhanced product lines related to managing, engineering, and detecting biofilms. There are three types of physical modes of debridement: manual debridement, pulse electrical field debridement, and ultrasound debridement.

The Acute Wounds Segment Dominate the Anti-biofilm Wound Dressing Market

Based on wound type, the anti-biofilm wound dressing market is segmented into acute and chronic wounds. In 2023, surgical & traumatic wounds held a significant share, due to the increasing number of trauma cases worldwide. The acute wound segment dominated the market. This segment is expected to grow by 9.3%.

Traumatic wounds are sudden injuries that can range from minor ones to severe ones, like gunshot wounds. Such wounds include abrasions, lacerations, skin tears, bites, and penetrating trauma wounds. Anti-biofilm wound dressings are ideal for treating these types of wounds.

When treating traumatic wounds with these dressings, the body's underlying tissues are repaired, foreign particles are removed, and wounds are allowed to drain. Preventing infections and promoting healing, these steps can promote segment growth and help prevent infections.

Regions Leading in Anti-biofilm Wound Dressing Market: Country-Wise Analysis

Anti-biofilm Wound Dressing Market Outlook in the United States

The United States accounts for a significant market share in North America r and is estimated to record a CAGR of 9.5%. An increase in chronic wounds, a rise in road accidents, and the presence of large ambulatory surgical centers are a few factors that drive market growth in this region. Well-developed infrastructure, skilled staff, and increased healthcare expenditures contribute to this region's market growth.

Anti-biofilm Wound Dressing Market is Becoming Mainstream in the United Kingdom

Europe's significant region, the United Kingdom, is expected to record a CAGR of 9.1%. Wounds are a growing concern in Europe, and their treatment involves a variety of resources. Various surveys were conducted in the United Kingdom.

According to statistics, three to four wounds per 1,000 people are reported. Diabetic foot ulcers are estimated to be diagnosed between 400,000 and 600,000 each year, along with venous leg ulcers that number about one million.

The United Kingdom's anti-biofilm wound dressing market is expected to grow due to the aging population and the increased prevalence of long-term chronic conditions.

Promising Market Share of Anti-biofilm Wound Dressing in China

Various studies conducted in China estimate that around 100 million patients require wound care every year, and about 30 million of these are skin wounds. These factors are expected to drive the market in China. An increase in healthcare expenditure, an increase in road accidents, and a significant amount of patient population are expected to drive the market.

The number of wound care centers in China has increased from 16 in 2010 to 357 in 2019. In December 2019, the National Health Commission of China released a notice for promoting the management of diagnosis and treatment of chronic skin wounds. This system includes setting up wound treatment departments and training specialized doctors & nurses.

The population of China is covered by social health insurance for more than 95%, which includes all primary healthcare institutions, public hospitals, as well as some private hospitals. As a result, chronic wounds are on the rise in China, government initiatives are being implemented, and healthcare facilities are being improved, which is expected to drive the market.

Start-up Ecosystem: The Anti-biofilm Wound Dressing Market

It seems that several new industry players are concentrating their efforts on consolidating their distribution channels. They are also focusing on direct marketing as a way of getting a foothold in the anti-biofilm wound dressing market.

To gain an advantage over their competitors, numerous key players are still focusing on partnerships and innovation in product development as their primary strategies to gain an advantage over their competitors.

For instance, a telehealth platform developed by Wound Pros Inc. in January 2021 enables patients and professionals to communicate. Their app, RITA, facilitates new wound measurements and diagnostics.

Competitive Landscape

Inflows of Funds are Expected as Market Players Expand their Footprints

Leading companies are leaving no stone unturned to gain a competitive edge and boost the anti-biofilm wound dressing market outlook.

For Instance:

• Triad Life Sciences Inc. was acquired by Convatec Inc. for US$ 450 million in March 2022. With the acquisition, Convatec intends to strengthen its portfolio of biologically derived innovative products for surgical wounds, chronic wounds, and burns.
• A newly FDA-cleared antimicrobial matrix product from Imbed Biosciences, Microlyte Matrix, was announced in April 2021. The product is intended for use in the treatment of surgical, traumatic, and chronic wounds.
• The ConvaTec Group Plc (ConvaTec) launched an innovative new medication called "ConvaMax" in January 2020 to treat diabetic foot ulcers, pressure ulcers, leg ulcers, and dehisced surgical wounds. The product is available in non-adhesive forms as well, allowing total freedom when integrating compression bands or a main dressing to support the care regimen.
• Microlyte Ag was introduced to the market in January 2018, after Imbed Biosciences raised more than USD 1.6 million to research silver-based anti-biofilm wound dressings.
• Smith & Nephew PLC acquired Osiris Therapeutics, Inc. in April 2019, a company specializing in regenerative medicine. As a result of this acquisition, the company will expand its product portfolio for advanced wound management, increasing the company's market share and customer base. This initiative is intended to boost the company's growth.

Some of the Prominent Players in the Anti-Biofilm Wound Dressing Market are as Follows

• ConvaTec
• Smith & Nephew PLC
• Urgo Medical
• Coloplast
• 3M

Scope of Report

Anti-biofilm Wound Dressing Market Segmentation by Category

By Mode of Mechanism:

• Physical
• Chemical
• Biological

By Wound Type:

• Chronic Wounds
• Acute Wounds

By End User:

• Hospitals and Clinics
• Surgical Centers
• Other End users

By Region:

• North America
• Latin America
• Europe
• The Middle East & Africa (MEA)
• East Asia